Founded in May 2017, AurorA-TT is a Technology Transfer Intermediation Company based in Milano, Italy. AurorA-TT identifies promising scientific breakthroughs and companies from academia, research centers, entrepreneurs and other entities to accompany them to industrial success and to partner with biopharma companies to reach the market. Guido Guidi, MD serves as Chairman, Edoardo Negroni, MBA and Gabriele Campi, PhD, serve as Managing Partners and Paolo Rizzardi, MD and PierluigiParacchi as Venture Partners.
More information:

Rottapharm Biotech

Rottapharm Biotech is an R&D company dedicated to innovative drug discovery and development. Rottapharm Biotech operates with an integrated discovery model that includes new chemical entities and a proprietary technology platform for the generation and selection of monoclonal antibodies. The R&D expertise embraces medicinal/computational chemistry, new target validation, pharmacological and pharmacokinetic characterization of new drug candidates, and design and conduct of innovative clinical trials. The company pipeline covers different therapeutic areas with focus on rheumatology, pain and inflammation, immunomodulation and immuno-oncology, and selected oncology areas. The company strategy is to look for partnerships at an early stage of development, ranging from preclinical significant stages to phase II proof-of-concept trials.
More information:


ItalfarmacoSpA is a specialty pharmaceutical company of the Italfarmaco Group engaged in the discovery, development, manufacturing and marketing of branded prescription and non-prescription products in more than 60 countries on 5 continents. Italfarmaco’s research and development expertise is best demonstrated through its HDAC inhibitor development programs, addressing new therapeutic treatments of specialty and rare diseases. Through both marketed drugs and development programs, Italfarmaco is dedicated to serving patients whose needs remain largely unmet.
More information: